U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test Devices
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test Devices Guidance for Industry and Food and Drug Administration Staff February 2019

Download the Final Guidance Document Read the Federal Register Notice
Final
Docket Number:
FDA-2016-D-2561
Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health

This guidance is intended to assist drug sponsors and device manufacturers who are planning to develop new antimicrobial drugs and antimicrobial susceptibility test (AST) devices and who seek to coordinate development of these products such that the AST device could be cleared either at the time of new drug approval or shortly thereafter.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2016-D-2561.

Back to Top